Advisory Services Network’s Enanta Pharmaceuticals ENTA Stock Holding History

Advisory Services Network’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4	Closed	-$51	–	2898
2026 Q1	$51	Buy	+4	New	+$54	﹤0.01%	4757
2025 Q4	–	Sell	-4	Closed	-$48	–	2529
2025 Q3	$48	Buy	+4	New	+$32	﹤0.01%	4467
2020 Q4	–	Sell	-262	Closed	-$12K	–	3401
2020 Q3	$12K	Buy	+262	New	+$12.7K	﹤0.01%	2325
2016 Q3	$8K	Buy	+300	New	+$6.97K	﹤0.01%	1372

Other funds holding ENTA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Advisory Services Network's ENTA Position: Q2 2026 in Review

Advisory Services Network sold out of Enanta Pharmaceuticals (ENTA) in Q2 2026, closing a stake of 4 shares — an estimated $51 sold.

Advisory Services Network first reported a position in ENTA in Q3 2016 and held it in 4 quarters. The position peaked at $12K in Q3 2020. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

Advisory Services Network reported no remaining Enanta Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Advisory Services Network sold 4 Enanta Pharmaceuticals shares in Q2 2026, an estimated $51.
Advisory Services Network first reported a position in Enanta Pharmaceuticals in Q3 2016 and held it in 4 quarters.
Advisory Services Network's Enanta Pharmaceuticals position peaked at $12K in Q3 2020.
123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.